KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $50.3 million.

  • Castle Biosciences' Share-based Compensation fell 7.12% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 9.39%. This contributed to the annual value of $50.3 million for FY2024, which is 1.76% down from last year.
  • Latest data reveals that Castle Biosciences reported Share-based Compensation of $50.3 million as of FY2024, which was down 1.76% from $51.2 million recorded in FY2023.
  • Castle Biosciences' Share-based Compensation's 5-year high stood at $51.2 million during FY2023, with a 5-year trough of $8.3 million in FY2020.
  • For the 3-year period, Castle Biosciences' Share-based Compensation averaged around $46.0 million, with its median value being $50.3 million (2024).
  • As far as peak fluctuations go, Castle Biosciences' Share-based Compensation spiked by 565.25% in 2020, and later decreased by 1.76% in 2024.
  • Castle Biosciences' Share-based Compensation (Yearly) stood at $8.3 million in 2020, then soared by 161.64% to $21.7 million in 2021, then surged by 67.07% to $36.3 million in 2022, then spiked by 41.02% to $51.2 million in 2023, then decreased by 1.76% to $50.3 million in 2024.